News Related to Eisai Innovation

Related coverage linked through entity extraction aliases.

Sift Biosciences closes $3.7 million pre-seed financing for T-cell booster platform

Apr 10, 2026

Sift Biosciences closed an oversubscribed $3.7 million pre-seed round to advance a peptide immunotherapy platform designed to activate pre-existing memory T cells. The financing will fund in vivo studies, expansion of its AI-powered discovery engine, and oncology lead selection.

Sift Biosciences Closes $3.7M Pre-Seed Round for Peptide Immunotherapy Platform

Feb 19, 2026

Sift Biosciences, a UC Berkeley spinout, closed an oversubscribed $3.7 million pre-seed financing to advance its AI-driven peptide immunotherapy platform targeting immunologically "cold" solid tumors.